Serum soluble interleukin-2 receptor as a biomarker in immunoglobulin G4-related disease

Tomohiro Handa, Shoko Matsui, Hajime Yoshifuji, Yuzo Kodama, Hiroshi Yamamoto, Seijiro Minamoto, Yuko Waseda, Yasuharu Sato, Keishi Kubo, Tsuneyo Mimori, Tsutomu Chiba, Toyohiro Hirai, Michiaki Mishima

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objectives: Serum soluble interleukin-2 (IL-2) receptor (sIL-2R) might reflect disease activity in immunoglobulin G4-related disease (IgG4-RD). We aimed to elucidate the clinical significance of blood markers, including sIL-2R, in patients with IgG4-RD. Methods: We enrolled 59 patients with IgG4-RD and investigated the association between blood markers (white blood cells, C-reactive protein, sIL-2R, IgG, IgG4, IgE, total hemolytic complement), and clinical indices. Results: At baseline, serum sIL-2R (Rs = 0.532, p <.001) and IgG4 (Rs = 0.545, p <.001) levels showed significant correlation to the number of organs involved. During follow-up period (median, 70 months; range, 7–195 months), 40 patients were treated with corticosteroids. Receiver operating characteristic (ROC) analysis showed that baseline sIL-2R levels most accurately predicted patients requiring glucocorticoid treatment (area under the ROC curve, 0.807). Among the 46 patients who improved, sIL-2R and IgG4 levels decreased in 42 and 41 patients, respectively. Among them, serum sIL-2R levels decreased to a normal range in 42 patients (91%), whereas IgG4 levels normalized in 19 (41%). Conclusion: The serum sIL-2R level is a potential biomarker for IgG4-RD that may reflect the number of involved organs and may predict patients requiring glucocorticoid treatment.

Original languageEnglish
Pages (from-to)838-844
Number of pages7
JournalModern Rheumatology
Volume28
Issue number5
DOIs
Publication statusPublished - Sep 3 2018

Keywords

  • Biomarker
  • IgG4-related disease
  • soluble IL-2 receptor

ASJC Scopus subject areas

  • Rheumatology

Fingerprint Dive into the research topics of 'Serum soluble interleukin-2 receptor as a biomarker in immunoglobulin G4-related disease'. Together they form a unique fingerprint.

  • Cite this

    Handa, T., Matsui, S., Yoshifuji, H., Kodama, Y., Yamamoto, H., Minamoto, S., Waseda, Y., Sato, Y., Kubo, K., Mimori, T., Chiba, T., Hirai, T., & Mishima, M. (2018). Serum soluble interleukin-2 receptor as a biomarker in immunoglobulin G4-related disease. Modern Rheumatology, 28(5), 838-844. https://doi.org/10.1080/14397595.2017.1416739